192 related articles for article (PubMed ID: 21712498)
41. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
42. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers.
Martin PD; Kemp J; Dane AL; Warwick MJ; Schneck DW
J Clin Pharmacol; 2002 Dec; 42(12):1352-7. PubMed ID: 12463730
[TBL] [Abstract][Full Text] [Related]
43. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
[TBL] [Abstract][Full Text] [Related]
44. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.
Song I; Min SS; Borland J; Lou Y; Chen S; Patel P; Ishibashi T; Piscitelli SC
J Clin Pharmacol; 2011 Feb; 51(2):237-42. PubMed ID: 20489027
[TBL] [Abstract][Full Text] [Related]
45. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial.
Lee FJ; Monteiro P; Baker D; Bloch M; Roth N; Finlayson R; Moore R; Hoy J; Martinez E; Carr A
HIV Med; 2016 Sep; 17(8):605-14. PubMed ID: 26987376
[TBL] [Abstract][Full Text] [Related]
46. The effect of erythromycin on the pharmacokinetics of rosuvastatin.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Raza A; Schneck DW
Eur J Clin Pharmacol; 2003 May; 59(1):51-6. PubMed ID: 12682802
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of alternate day versus daily dosing of rosuvastatin.
Dulay D; LaHaye SA; Lahey KA; Day AG
Can J Cardiol; 2009 Feb; 25(2):e28-31. PubMed ID: 19214297
[TBL] [Abstract][Full Text] [Related]
48. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
Clin Drug Investig; 2008; 28(8):479-85. PubMed ID: 18598093
[TBL] [Abstract][Full Text] [Related]
49. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics.
Simonson SG; Martin PD; Mitchell PD; Lasseter K; Gibson G; Schneck DW
J Clin Pharmacol; 2005 Aug; 45(8):927-34. PubMed ID: 16027403
[TBL] [Abstract][Full Text] [Related]
50. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
Kakuda TN; Abel S; Davis J; Hamlin J; Schöller-Gyüre M; Mack R; Ndongo N; Petit W; Ridgway C; Sekar V; Tweedy S; Hoetelmans RM
Antimicrob Agents Chemother; 2011 May; 55(5):2290-6. PubMed ID: 21383098
[TBL] [Abstract][Full Text] [Related]
52. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
Olsson AG; McTaggart F; Raza A
Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.
Sekar VJ; Lefebvre E; De Pauw M; Vangeneugden T; Hoetelmans RM
Br J Clin Pharmacol; 2008 Aug; 66(2):215-21. PubMed ID: 18460033
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.
Sekar VJ; Lefebvre E; Mariën K; De Pauw M; Vangeneugden T; Hoetelmans RM
Ther Drug Monit; 2007 Dec; 29(6):795-801. PubMed ID: 18043478
[TBL] [Abstract][Full Text] [Related]
55. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
Moltó J; Valle M; Miranda C; Cedeño S; Negredo E; Barbanoj MJ; Clotet B
Antimicrob Agents Chemother; 2011 Jan; 55(1):326-30. PubMed ID: 21078942
[TBL] [Abstract][Full Text] [Related]
56. Treatment and prevention of dyslipidemia with rosuvastatin (Crestor).
Leonard KA
Nurse Pract; 2004 May; 29(5):11-5. PubMed ID: 15167530
[No Abstract] [Full Text] [Related]
57. Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.
Kakuda TN; Sekar V; Lavreys L; De Paepe E; Stevens T; Vanstockem M; Vangeneugden T; Hoetelmans RM
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):346-52. PubMed ID: 27129006
[TBL] [Abstract][Full Text] [Related]
58. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics.
Martin PD; Schneck DW; Dane AL; Warwick MJ
Curr Med Res Opin; 2008 Apr; 24(4):1231-5. PubMed ID: 18355422
[TBL] [Abstract][Full Text] [Related]
59. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
Foley-Comer AJ; Young AM; Russell-Yarde F; Jordan P
Expert Opin Investig Drugs; 2011 Jan; 20(1):3-12. PubMed ID: 21114416
[TBL] [Abstract][Full Text] [Related]
60. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
